Collaborating on a project called the Future of Radiation Therapy—aimed at revolutionizing radiation therapy, Moffitt Cancer Center and Cvergenx are providing a personalized radiation treatment plan based on the patients genetic framework! Read on, below, for more information!
Moffitt’s Radiation Oncology Department will utilize Cvergenx’s Genomic-Adjusted Radiation Dose (GARD) model. GARD is the first validated model that can predict the therapeutic effects of radiotherapy and guide dosage based on an individual patient’s radiosensitivity. It works by combining two algorithms – the linear-quadratic (LQ) model, which helps identify dosing strategies, and the radiosensitivity index (RSI), which evaluates expression levels of 10 different genes that have been found to predict tumor radiosensitivity. The RSI was developed by Javier Torres-Roca, M.D., associate member of Moffitt’s Radiation Oncology Department.
Together, the LQ model and RSI data result in GARD scoring. Patients with high GARD values have the likelihood of a positive therapeutic response to radiation therapy. Lower GARD values indicate resistance to radiation.
“Utilizing radiosensitivity and genomic-adjusted dosage will reduce unnecessary radiation treatment, as well as fine tune more effective treatment for those cancer patients who stand to benefit,” said Louis B. Harrison, M.D., FASTRO, chair of the Department of Radiation Oncology at Moffitt. “Genomics is an essential ingredient of our multi-faceted strategy to personalize radiation therapy. By taking a more tailored approach to the treatment of each individual patient, , we will be able to improve oncologic outcomes and reduce health care costs.”
“Our strategic collaboration with Moffitt represents a pivotal moment in the development and use of precision genomic radiation planning and therapy,” said Raymond F. Vennare CEO of Cvergenx, Inc. “The ability to introduce an enabling technology like ours into a clinical environment like Moffitt, not only shifts the paradigm in radiation planning and treatment, but has the potential to create an entirely new paradigm in radiation oncology as well.”
This article was originally posted by Moffitt.org